H1N1 Infection Pipeline Review H2 2013:Industry Analysis Report @ http://www.researchmoz.us/h1n1-infection-pipeline-review-h2-2013-report.html

1. H1N1 Infection - Pipeline Review, H2 2013
H1N1 Infection - Pipeline Review, H2 2013
Summary
Global Markets Directs, 'H1N1 Infection - Pipeline Review, H2 2013', provides an overview of the indications
therapeutic pipeline. This report provides information on the therapeutic development for H1N1 Infection,
complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key
players involved in the therapeutic development for H1N1 Infection. H1N1 Infection - Pipeline Review, Half
Year is built using data and information sourced from Global Markets Directs proprietary databases,
Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets Directs
team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data
for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for H1N1 Infection.
- A review of the H1N1 Infection products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the H1N1 Infection pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for H1N1 Infection.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to
gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding H1N1 Infection pipeline depth and focus
of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the
most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that
drove them from pipeline.
H1N1 Infection - Pipeline Review, H2 2013

2. Table Of Contents
table Of Contents 2
list Of Tables 5
list Of Figures 6
introduction 7
global Markets Direct Report Coverage 7
h1n1 Infection Overview 8
therapeutics Development 9
an Overview Of Pipeline Products For H1n1 Infection 9
h1n1 Infection Therapeutics Under Development By Companies 11
h1n1 Infection Therapeutics Under Investigation By Universities/institutes 15
late Stage Products 16
comparative Analysis 16
mid Clinical Stage Products 17
comparative Analysis 17
early Clinical Stage Products 18
comparative Analysis 18
discovery And Pre-clinical Stage Products 19
comparative Analysis 19
h1n1 Infection Therapeutics - Products Under Development By Companies 20
h1n1 Infection Therapeutics - Products Under Investigation By Universities/institutes 23
companies Involved In H1n1 Infection Therapeutics Development 24
baxter International Inc. 24
johnson & Johnson 25
sanofi-aventis 26
glaxosmithkline Plc 27
inovio Biomedical Corporation 28
celltrion, Inc. 29
novartis Ag 30
cel-sci Corporation 31
avi Biopharma Inc. 32
opko Health, Inc. 33
medicago Inc. 34
nanoviricides, Inc. 35
novabay Pharmaceuticals, Inc. 36
medigen Biotechnology Corp. 37
xoma Ltd. 38
cytos Biotechnology Ag 39
synairgen Plc 40
bioalliance Pharma Sa 41
antigen Express, Inc. 42
colby Pharmaceutical Company 43
marinomed Biotechnologie Gmbh 44
H1N1 Infection - Pipeline Review, H2 2013

3. ligocyte Pharmaceuticals, Inc. 45
pt. Bio Farma 46
technovax, Inc. 47
alphavax, Inc. 48
epivax, Inc. 49
kineta, Inc. 50
replicor Inc. 51
protein Sciences Corporation 52
etubics Corporation 53
canopus Biopharma Incorporated 54
ibio, Inc. 55
sirnaomics, Inc. 56
vaxart, Inc. 57
serum Institute Of India Limited 58
immuneregen Biosciences, Inc. 59
cilian Ag 60
revivicor, Inc. 61
vaxine Pty Ltd 62
beijing Minhai Biotechnology Co., Ltd 63
h1n1 Infection - Therapeutics Assessment 64
assessment By Monotherapy Products 64
assessment By Combination Products 65
assessment By Route Of Administration 66
assessment By Molecule Type 68
drug Profiles 70
homspera - Drug Profile 70
flu Vaccine - Drug Profile 72
nv-inf-2 - Drug Profile 73
rep-9-ac - Drug Profile 74
h1n1 Vaccine - Drug Profile 76
vaccine For Pandemic Influenza (h1 & H5) - Drug Profile 78
nvc-612 - Drug Profile 79
panblok - Drug Profile 80
influenza Vaccine - Drug Profile 82
interferon Beta - Drug Profile 83
pandemic Flu Vaccine - Drug Profile 85
gsk-2340273a - Drug Profile 86
stp-702 - Drug Profile 89
f-10 Antibody Program - Drug Profile 90
tvx-002 - Drug Profile 91
radavirsen - Drug Profile 92
(statin + Caffeine) - Drug Profile 93
hac1 Vaccine - Drug Profile 94
H1N1 Infection - Pipeline Review, H2 2013

4. mf59-eh1n1 Influenza Vaccine - Drug Profile 95
influenza Vlp Vaccine - Drug Profile 96
pandemic H1n1 Vaccine - Drug Profile 97
h1n1 Flu Treatment - Drug Profile 98
influenza Vaccine Qb-flu - Drug Profile 99
iota-carrageenan - Drug Profile 100
tmb-571 - Drug Profile 102
flufirvitide-3 - Drug Profile 103
trimeric Aichi Ha Vaccine - Drug Profile 104
jvrs-100 + Universal Influenza Vaccine - Drug Profile 105
influenza Vaccine - Drug Profile 107
ino-3510 - Drug Profile 108
ino-3401 - Drug Profile 110
aea-35p - Drug Profile 112
ino-3605 - Drug Profile 113
ino-3609 - Drug Profile 115
h1n1 Influenza Vaccine - Drug Profile 117
innate Immune Agonists - Drug Profile 119
h1n1 Syncon Universal Influenza Vaccine - Drug Profile 120
ba-032 - Drug Profile 121
trivalent Live-attenuated Influenza Vaccine - Drug Profile 122
ciflu - Drug Profile 124
human Antibody Based Vaccines - Drug Profile 126
chimigen Influenza Vaccine - Drug Profile 128
universal Flu Vaccine - Drug Profile 129
h1n1 Pandemic Flu Vaccine - Drug Profile 130
matriptase Inhibitors - Drug Profile 131
greflu/cal - Drug Profile 132
pam2cys - Drug Profile 133
pam2cys Vaccine - Drug Profile 134
h1n1 Genetic Vaccine - Drug Profile 135
h1n1 Infection Therapeutics - Drug Profile Updates 136
h1n1 Infection Therapeutics - Dormant Products 149
h1n1 Infection - Product Development Milestones 150
featured News & Press Releases 150
appendix 159
methodology 159
coverage 159
secondary Research 159
primary Research 159
expert Panel Validation 159
contact Us 160
disclaimer 160
H1N1 Infection - Pipeline Review, H2 2013

5. ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
H1N1 Infection - Pipeline Review, H2 2013